Pasithea Therapeutics Postpones Special Meeting until December 9, 2022 at 9:00 AM Eastern Time
28 Novembro 2022 - 9:05PM
Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the
“Company”), a biotechnology company focused on the discovery,
research and development of innovative treatments for central
nervous system (“CNS”) disorders, today announced that it has
postponed its Special Stockholder Meeting (the “Special Meeting”)
originally scheduled for November 29, 2022 to allow additional time
for stockholder voting proxies (the “Notice”). The Special Meeting
will now be held on December 9, 2022 at 9:00 am
Eastern Time at One Vanderbilt Avenue, 67th Floor, New York,
NY 10017. There have been no changes to the proposals to be
voted on at the Special Meeting. The Board of Directors of the
Company (the “Board”) has called this Special Meeting of the
Company’s stockholders, in response to the formal request of
Concord IP2 Ltd., Elderhill Corporation, Leonite Capital LLC, Camac
Partners, LLC, Leonite Fund I, LP, Camac Capital, LLC, Camac Fund,
LP, David Delaney, Avi Geller and Eric Shahinian (collectively, the
“Dissident Group”), for stockholders to vote on the certain
proposals submitted by the Dissident Group.
The record date for the Special Meeting remains
November 9, 2022.
Additional Information and Where to Find
It
In connection with the Special Meeting, the
Company filed a definitive proxy statement on Schedule 14A on
November 15, 2022, with the Securities and Exchange Commission (the
“SEC”). STOCKHOLDERS OF THE COMPANY ARE URGED TO READ THE PROXY
STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY
OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE SPECIAL MEETING
THAT THE COMPANY FILES WITH THE SEC WHEN THEY BECOME AVAILABLE
BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE BUSINESS
TO BE CONDUCTED AT THE SPECIAL MEETING. The definitive proxy
statement, and any other documents filed by the Company with the
SEC may be obtained free of charge at the SEC’s website at
www.sec.gov or at the “Investors” section of our website at
www.pasithea.com or by writing to our solicitor, Kingsdale
Advisors, by phone toll-free at 1-866-581-1514, or call collect
outside North America at 646-854-8013, or by email at
contactus@kingsdaleadvisors.com. Information about the Company’s
directors and executive officers and their ownership of the Company
securities is set forth in the Company’s definitive proxy statement
for the Special Meeting on Schedule 14A filed with the SEC on
November 15, 2022. You can obtain free copies of the definitive
proxy statement as described in the preceding paragraph.
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corporation is a biotechnology company
focused on the discovery, research and development of innovative
treatments for central nervous system (CNS) disorders. With an
experienced team of experts in the fields of neuroscience and
psychopharmacology, Pasithea is developing new molecular entities
for the treatment of neurological disorders, including Amyotrophic
Lateral Sclerosis (ALS) and Multiple Sclerosis, Neurofibromatosis
type 1 and Noonan syndrome.
Forward Looking Statements
This press release contains statements that
constitute “forward-looking statements.” Forward-looking statements
are subject to numerous conditions, many of which are beyond the
control of the Company. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to the Company on the date of this
release. These forward-looking statements are based upon current
estimates and assumptions and are subject to various risks and
uncertainties, including, without limitation, those set forth in
the Company’s filings with the SEC. Thus, actual results could be
materially different. The Company undertakes no obligation to
update these statements whether as a result of new information,
future events or otherwise, after the date of this release, except
as required by law.
Company Contact
Dr. Tiago Reis MarquesChief Executive OfficerE:
tiago@pasithea.com
Investor Relations Contact
Lisa M. WilsonIn-Site Communications, Inc.T: 212-452-2793E:
lwilson@insitecony.com
Pasithea Therapeutics (NASDAQ:KTTAW)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Pasithea Therapeutics (NASDAQ:KTTAW)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024